Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.

Dehghani L, Mikail N, Kramkimel N, Soyer P, Lebtahi R, Mallone R, Larger E.

Eur J Cancer. 2018 Nov;104:243-246. doi: 10.1016/j.ejca.2018.09.014. Epub 2018 Oct 25. No abstract available.

PMID:
30454710
2.

Sporadic pancreatic neuroendocrine tumor: Surgery of the primary tumor.

Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R.

J Visc Surg. 2018 Nov 15. pii: S1878-7886(18)30124-3. doi: 10.1016/j.jviscsurg.2018.08.010. [Epub ahead of print]

PMID:
30448206
3.

LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial.

Bouattour M, Assenat E, Guiu B, Ilonca Alina D, Pageaux GP, Sibert A, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Pereira H, Castera L, Chatellier G, Vilgrain V; SARAH Trial Group.

Ann Oncol. 2017 Jun 1;28(suppl_3). doi: 10.1093/annonc/mdx302. No abstract available.

PMID:
30052793
4.

Preoperative imaging and pathologic classification for pancreatic neuroendocrine tumors.

Deguelte S, de Mestier L, Hentic O, Cros J, Lebtahi R, Hammel P, Kianmanesh R.

J Visc Surg. 2018 Apr;155(2):117-125. doi: 10.1016/j.jviscsurg.2017.12.008. Epub 2018 Feb 12. Review.

PMID:
29397338
5.

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group.

Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.

PMID:
29107679
6.

18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation.

Bucau M, Laurent-Bellue A, Poté N, Hentic O, Cros J, Mikail N, Rebours V, Ruszniewski P, Lebtahi R, Couvelard A.

Neuroendocrinology. 2018;106(3):274-282. doi: 10.1159/000480239. Epub 2017 Aug 11.

PMID:
28803235
7.

[18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis.

Justet A, Laurent-Bellue A, Thabut G, Dieudonné A, Debray MP, Borie R, Aubier M, Lebtahi R, Crestani B.

Respir Res. 2017 Apr 27;18(1):74. doi: 10.1186/s12931-017-0556-3.

8.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators.

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

9.

High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy.

Brieau B, Hentic O, Lebtahi R, Palazzo M, Ben Reguiga M, Rebours V, Maire F, Hammel P, Ruszniewski P, Fenaux P.

Endocr Relat Cancer. 2016 May;23(5):L17-23. doi: 10.1530/ERC-15-0543. Epub 2016 Mar 1. No abstract available.

PMID:
26932783
10.

Differences in Alimentary Glucose Absorption and Intestinal Disposal of Blood Glucose After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy.

Cavin JB, Couvelard A, Lebtahi R, Ducroc R, Arapis K, Voitellier E, Cluzeaud F, Gillard L, Hourseau M, Mikail N, Ribeiro-Parenti L, Kapel N, Marmuse JP, Bado A, Le Gall M.

Gastroenterology. 2016 Feb;150(2):454-64.e9. doi: 10.1053/j.gastro.2015.10.009. Epub 2015 Oct 23.

11.

Implementation and validation of collapsed cone superposition for radiopharmaceutical dosimetry of photon emitters.

Sanchez-Garcia M, Gardin I, Lebtahi R, Dieudonné A.

Phys Med Biol. 2015 Oct 21;60(20):7861-76. doi: 10.1088/0031-9155/60/20/7861. Epub 2015 Sep 25.

PMID:
26406778
12.

Somatostatin receptor subtype 2 expression and somatostatin receptor scintigraphy positivity in pancreatic serous cystadenomas.

Poté N, Lebtahi R, Hentic O, Speisky D, Sauvanet A, Vullierme MP, Bedossa P, Ruszniewski P, Couvelard A.

Pancreas. 2015 May;44(4):672-4. doi: 10.1097/MPA.0000000000000319. No abstract available.

PMID:
25872132
13.

Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.

Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group.

Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474.

14.

Diagnostic value of ⁹⁹mTc-HMPAO-labeled leukocytes scintigraphy in suspicion of post-sternotomy mediastinitis relapse.

Rouzet F, de Labriolle-Vaylet C, Trouillet JL, Hitzel A, Benali K, Lebtahi R, Le Guludec D.

J Nucl Cardiol. 2015 Feb;22(1):123-9. doi: 10.1007/s12350-014-9999-9. Epub 2014 Oct 8.

PMID:
25287738
15.

A new approach for dose calculation in targeted radionuclide therapy (TRT) based on collapsed cone superposition: validation with (90)Y.

Sanchez-Garcia M, Gardin I, Lebtahi R, Dieudonné A.

Phys Med Biol. 2014 Sep 7;59(17):4769-84. doi: 10.1088/0031-9155/59/17/4769. Epub 2014 Aug 6.

PMID:
25097006
16.

Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.

de Mestier L, Dromain C, d'Assignies G, Scoazec JY, Lassau N, Lebtahi R, Brixi H, Mitry E, Guimbaud R, Courbon F, d'Herbomez M, Cadiot G.

Endocr Relat Cancer. 2014 Apr 28;21(3):R105-20. doi: 10.1530/ERC-13-0365. Print 2014 Jun. Review.

PMID:
24351682
17.

Role of radiolabelled leucocyte scintigraphy in patients with a suspicion of prosthetic valve endocarditis and inconclusive echocardiography.

Hyafil F, Rouzet F, Lepage L, Benali K, Raffoul R, Duval X, Hvass U, Iung B, Nataf P, Lebtahi R, Vahanian A, Le Guludec D.

Eur Heart J Cardiovasc Imaging. 2013 Jun;14(6):586-94. doi: 10.1093/ehjci/jet029. Epub 2013 Mar 1.

PMID:
23456094
18.

Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods.

Dieudonné A, Hobbs RF, Lebtahi R, Maurel F, Baechler S, Wahl RL, Boubaker A, Le Guludec D, Sgouros G, Gardin I.

J Nucl Med. 2013 Feb;54(2):236-43. doi: 10.2967/jnumed.112.105825. Epub 2012 Dec 18.

19.

Recurrence after surgical resection of gastrinoma: who, when, where and why?

Maire F, Sauvanet A, Couvelard A, Rebours V, Vullierme MP, Lebtahi R, Hentic O, Belghiti J, Hammel P, Lévy P, Ruszniewski P.

Eur J Gastroenterol Hepatol. 2012 Apr;24(4):368-74. doi: 10.1097/MEG.0b013e328350f816.

PMID:
22410712
20.

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study.

Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, Israel-Biet D, Lacronique J, Monnet I, Reynaud-Gaubert M, Tazi A, Lebtahi R, Debray MP, Brauner M, Dehoux M, Dornic Q, Aubier M, Mentré F, Duval X.

Eur Respir J. 2012 Mar;39(3):772-5. doi: 10.1183/09031936.00113011. No abstract available.

21.

[Diagnosis, staging and follow-up of neuroendocrine tumors: role of somatostatin receptors scintigraphy].

Lebtahi R.

Ann Pathol. 2011 Nov;31(5 Suppl):S83-4. doi: 10.1016/j.annpat.2011.08.017. Epub 2011 Sep 25. French. No abstract available.

PMID:
22054471
22.

Clinical feasibility of fast 3-dimensional dosimetry of the liver for treatment planning of hepatocellular carcinoma with 90Y-microspheres.

Dieudonné A, Garin E, Laffont S, Rolland Y, Lebtahi R, Leguludec D, Gardin I.

J Nucl Med. 2011 Dec;52(12):1930-7. doi: 10.2967/jnumed.111.095232. Epub 2011 Nov 8.

23.

Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study.

Nguyen-Khac E, Ollivier I, Aparicio T, Moullart V, Hugentobler A, Lebtahi R, Lobry C, Susini C, Duhamel C, Hommel S, Cadranel JF, Joly JP, Barbare JC, Tramier B, Dupas JL.

Cancer Biol Ther. 2009 Nov;8(21):2033-9. Epub 2009 Nov 5.

PMID:
19738430
24.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.

Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society.

Neuroendocrinology. 2009;90(2):220-6. doi: 10.1159/000225951. Epub 2009 Aug 28.

PMID:
19713714
25.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.

Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, Vitek P, Sundin A, Plöckinger U; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society.

Neuroendocrinology. 2009;90(2):184-9. doi: 10.1159/000225946. Epub 2009 Aug 28. No abstract available.

PMID:
19713709
26.

Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.

Scigliano S, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P, Le Guludec D.

Endocr Relat Cancer. 2009 Sep;16(3):977-90. doi: 10.1677/ERC-08-0247. Epub 2009 May 26.

PMID:
19470616
27.

Early detection of right ventricular functional abnormalities in patients with complex right premature ventricular contractions.

Rouzet F, Sarda-Mantel L, Lebtahi R, Dinanian S, Frank R, Daou D, Leenhardt A, Slama MS, Le Guludec D.

Nucl Med Commun. 2008 Oct;29(10):901-6. doi: 10.1097/MNM.0b013e3283043a1c.

PMID:
18769308
28.

Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer.

Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, Vaylet C, Rougier P, André T, Gornet JM, Cherqui D, Delbaldo C, Panis Y, Talbot JN, Meignan M, Le Guludec D.

Br J Cancer. 2008 Mar 11;98(5):875-80. doi: 10.1038/sj.bjc.6604263. Epub 2008 Feb 26.

29.

Activation of somatostatin receptors attenuates pulmonary fibrosis.

Borie R, Fabre A, Prost F, Marchal-Somme J, Lebtahi R, Marchand-Adam S, Aubier M, Soler P, Crestani B.

Thorax. 2008 Mar;63(3):251-8. Epub 2007 Oct 19.

PMID:
17951277
30.

Myocardial uptake of 99mTc-annexin-V and 111In-antimyosin-antibodies after ischemia-reperfusion in rats.

Sarda-Mantel L, Hervatin F, Michel JB, Louedec L, Martet G, Rouzet F, Lebtahi R, Merlet P, Khaw BA, Le Guludec D.

Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):158-65. Epub 2007 Sep 5.

PMID:
17805532
31.

Evaluation of 99mTc-UBI 29-41 scintigraphy for specific detection of experimental Staphylococcus aureus prosthetic joint infections.

Sarda-Mantel L, Saleh-Mghir A, Welling MM, Meulemans A, Vrigneaud JM, Raguin O, Hervatin F, Martet G, Chau F, Lebtahi R, Le Guludec D.

Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1302-9. Epub 2007 Mar 3.

PMID:
17334764
32.

Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.

Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, Marchal J, Raguin O, Gruaz-Guyon A, Reubi JC, Le Guludec D, Crestani B.

J Nucl Med. 2006 Aug;47(8):1281-7.

33.

Imaging inflammatory cardiomyopathies.

Le Guludec D, Sarda L, Rouzet F, Merlet P, Slama MS, Lebtahi R.

J Nucl Cardiol. 2005 Nov-Dec;12(6):731-9. Review. No abstract available.

PMID:
16344235
34.

Lower limb hypertrophic osteoarthropathy can reveal aortic graft infection in Behçet syndrome.

de Lastours V, Lidove O, Lieberherr D, Laissy JP, Lebtahi R, Cerceau J, Lesèche G, Hayem G, Papo T.

Rheumatology (Oxford). 2006 Jan;45(1):117-8. Epub 2005 Nov 30. No abstract available.

PMID:
16319095
35.

Noninvasive evaluation of acute capillary permeability changes during high-volume ventilation in rats with and without hypercapnic acidosis.

Bouvet F, Dreyfuss D, Lebtahi R, Martet G, Le Guludec D, Saumon G.

Crit Care Med. 2005 Jan;33(1):155-60; discussion 250-2.

PMID:
15644663
36.

Automatic quantification of right ventricular function with gated blood pool SPECT.

Daou D, Van Kriekinge SD, Coaguila C, Lebtahi R, Fourme T, Sitbon O, Parent F, Slama M, Le Guludec D, Simonneau G.

J Nucl Cardiol. 2004 May-Jun;11(3):293-304.

PMID:
15173776
37.

The value of a completely automatic ECG gated blood pool SPECT processing method for the estimation of global systolic left ventricular function.

Daou D, Coaguila C, Benada A, Razzouk M, Haidar M, Colin P, Lebtahi R, Slama M, Guludec DL.

Nucl Med Commun. 2004 Mar;25(3):271-6.

PMID:
15094446
38.

Discordance between exercise SPECT lung Tl-201 uptake and left ventricular transient ischemic dilation in patients with CAD.

Daou D, Coaguila C, Delahaye N, Houzet F, Lebtahi R, Le Guludec D.

J Nucl Cardiol. 2004 Jan-Feb;11(1):53-61.

PMID:
14752473
39.

Comparative impact of standard approach, FDG PET and FDG dual-head coincidence gamma camera imaging in preoperative staging of patients with non-small-cell lung cancer.

Delahaye N, Crestani B, Rakotonirina H, Lebtahi R, Sarda L, Girard P, Charpentier E, Fery-Lemonnier E, Syrota A, Aubier M, Le Guludec D.

Nucl Med Commun. 2003 Dec;24(12):1215-24.

PMID:
14627847
40.

Inability of 99mTc-ciprofloxacin scintigraphy to discriminate between septic and sterile osteoarticular diseases.

Sarda L, Crémieux AC, Lebellec Y, Meulemans A, Lebtahi R, Hayem G, Génin R, Delahaye N, Huten D, Le Guludec D.

J Nucl Med. 2003 Jun;44(6):920-6.

41.

Comparative value of ECG-gated blood pool SPET and ECG-gated myocardial perfusion SPET in the assessment of global systolic left ventricular function.

Daou D, Vilain D, Colin P, Lebtahi R, Fourme T, Coaguila C, Benada A, Idy-Peretti I, Slama M, Le Guludec D.

Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):859-67. Epub 2003 Apr 4.

PMID:
12677300
42.

Performance of OSEM and depth-dependent resolution recovery algorithms for the evaluation of global left ventricular function in 201Tl gated myocardial perfusion SPECT.

Daou D, Pointurier I, Coaguila C, Vilain D, Benada AW, Lebtahi R, Fourme T, Slama M, Le Guludec D.

J Nucl Med. 2003 Feb;44(2):155-62.

43.

Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.

Lebtahi R, Le Cloirec J, Houzard C, Daou D, Sobhani I, Sassolas G, Mignon M, Bourguet P, Le Guludec D.

J Nucl Med. 2002 Jul;43(7):889-95.

44.

Identification of extensive coronary artery disease: incremental value of exercise Tl-201 SPECT to clinical and stress test variables.

Daou D, Delahaye N, Vilain D, Lebtahi R, Faraggi M, Le Guludec D.

J Nucl Cardiol. 2002 Mar-Apr;9(2):161-8.

PMID:
11986560
45.

Imaging appearances of metastases from neuroendocrine tumours of the pancreas.

Debray MP, Geoffroy O, Laissy JP, Lebtahi R, Silbermann-Hoffman O, Henry-Feugeas MC, Cadiot G, Mignon M, Schouman-Claeys E.

Br J Radiol. 2001 Nov;74(887):1065-70.

PMID:
11709476
46.

Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms.

Sarda L, Colin P, Boccara F, Daou D, Lebtahi R, Faraggi M, Nguyen C, Cohen A, Slama MS, Steg PG, Le Guludec D.

J Am Coll Cardiol. 2001 Mar 1;37(3):786-92.

47.

Clinical impact of combination of scatter, attenuation correction, and depth-dependent resolution recovery for (201)Tl studies.

Harel F, Génin R, Daou D, Lebtahi R, Delahaye N, Helal BO, Le Guludec D, Faraggi M.

J Nucl Med. 2001 Oct;42(10):1451-6.

48.

Electrocardiographically gated blood-pool SPECT and left ventricular function: comparative value of 3 methods for ejection fraction and volume estimation.

Daou D, Harel F, Helal BO, Fourme T, Colin P, Lebtahi R, Mariano-Goulart D, Faraggi M, Slama M, Le Guludec D.

J Nucl Med. 2001 Jul;42(7):1043-9.

49.

Prognostic value of 201Tl myocardial scintigraphy after coronary artery bypass grafting.

Sarda L, Fuchs L, Lebtahi R, Faraggi M, Delahaye N, Hvass U, Le Guludec D.

Nucl Med Commun. 2001 Feb;22(2):189-96. Erratum in: Nucl Med Commun 2001 May;22(5):605.

PMID:
11258406
50.

Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis.

Lebtahi R, Crestani B, Belmatoug N, Daou D, Genin R, Dombret MC, Palazzo E, Faraggi M, Aubier M, Le Guludec D.

J Nucl Med. 2001 Jan;42(1):21-6.

Supplemental Content

Loading ...
Support Center